AB

Abbott LaboratoriesNYSE ABT Stock Report

Last reporting period 30 Jun, 2024

Updated 13 Nov, 2024

Last price

Market cap $B

197.2

Mega

Exchange

XNYS - New York Stock Exchange, Inc

ABT Stock Analysis

AB

Neutral

Based on Eyestock quantitative analysis, ABT`s fundamental data and valuation indicate an investment grade of Neutral at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

71/100

Moderate score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

-6.0 %

Overvalued

Market cap $B

197.2

Dividend yield

1.88 %

Shares outstanding

1 737.95 B

Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. The company is headquartered in Abbott Park, Illinois and currently employs 115,000 full-time employees. The firm operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its Established Pharmaceutical Products segment includes gastroenterology products, women’s health products, cardiovascular and metabolic products, pain and central nervous system products and respiratory drugs and vaccines. Its Diagnostic Products segment includes core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion medicine; molecular diagnostics polymerase chain reaction (PCR) instrument systems; point of care systems; rapid diagnostics lateral flow testing products, and informatics and automation solutions. Its Nutritional Products segment includes various forms of infant formula and follow-on formula, adult and other pediatric nutritional products and others.

View Section: Eyestock Rating